{
    "nctId": "NCT05910710",
    "briefTitle": "Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",
    "officialTitle": "Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer, Neoadjuvant Chemotherapy, Pembrolizumab, Tumor Microenvironment",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Genomic profiling will be assessed by tissue and blood samples(analyze the TME changes)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Triple negative breast cancer\n* Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not\n* Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy\n* Sign to informed consent\n\nExclusion Criteria:\n\n* Patients with difficulty in obtaining sufficient samples",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}